Molecular Partners and Orano Med have dosed the first patients in a US Phase 1/2a trial of MP0712, a novel Radio-DARPin drug targeting DLL3, a protein highly expressed in small cell lung cancer and other neuroendocrine tumors. This therapy uses lead-212 to deliver targeted alpha radiation to tumors, aiming to improve treatment precision and reduce side effects. Initial safety and efficacy data are expected later in 2026, with comprehensive results anticipated in 2027. The trial is ongoing at five US sites, with more centers planned to open this year.
Sanoma Corporation has acquired Fluentbe, a Polish AI-powered online language tutoring platform, to enhance its K12 education offerings in Poland. Fluentbe, founded in 2015, serves over 40,000 students with personalized AI-driven language learning an...
Sanoma has acquired Fluentbe, a Polish digital language tutoring platform that uses AI to offer personalized language learning for individuals and companies. Fluentbe serves over 40,000 students and collaborates with more than 600 highly qualified tu...
Symbotic Inc. has acquired UK-based ARMS Innovations to enhance its warehouse automation with AI-driven operational intelligence. This acquisition enables Symbotic to offer a comprehensive Warehouse Operations Optimization platform that integrates au...
TomTom and Transit Technologies have formed a strategic partnership to integrate TomTom Orbis Maps and Live Traffic data into Transit Technologies’ fleet and logistics software. This integration enhances real-time routing intelligence for transit, pa...
Mohawk Industries will release its Q2 2026 financial results on July 30, followed by a live earnings call on July 31 at 11:00 a.m. ET. Investors can join via the company website or phone. Additionally, Mohawk announced a CEO succession plan: Paul De ...
